Clinical trials: Type 2 Diabetic Kidney Disease
Diabetic Nephropathies
Add-on Pentoxifylline to Losartan Versus Increasing Dose of Losartan on NT-PRO BNP in Type 2 Diabetics With Nephropathy
This study was designed to assess the efficacy of adding pentoxifylline to losartan in comparison with increasing dose of losartan in type 2 diabetes patients with nephropathy.
- Trial name
- NCT03006952
- Testing
- Pentoxifylline, Losartan
- Where
- Iran
- Volunteers
- 59 people
- Sponsor
- Tehran University of Medical Sciences
Chronic Kidney Diseases, Albuminuria
Diabetic Nephropathy in People With Diabetes. Prevalence and Predictive Factors
a prospective, observational, multi-center study with a cohort of 300 patients with Type 2 diabetes and macroalbuminuria. Prospectively we will collect kidney biopsies and analyse the transciptome of the kidney tissue and other…
- Conditions
- Chronic Kidney Diseases, Albuminuria, Diabetic Kidney Disease, Diabetic Nephropathies
- Trial name
- PRIMETIME2 (NCT04916132)
- Testing
- Kidney Biopsy
- Where
- 13 sites in Denmark
- Volunteers
- 300 people
- Sponsor
- Herlev Hospital
Diabetic Kidney Disease
The Multi-Center Clinical Study of Tang Shen Prescription on Type 2 Diabetic Kidney Disease in Early Stage
This study is a randomized, double-blinded, placebo-controlled clinical trial on type 2 diabetic Kidney Disease in early stage ( microalbuminuria excretion rate = 20-200mg/min) to evaluate the therapeutic effect of tang shen…
- Trial name
- NCT03009864
- Testing
- Tangshen Prescription
- Where
- China
- Volunteers
- 632 people
- Sponsor
- Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Focus Type 2 Diabetes Related Chronic Kidney Disease
Diabetic Kidney Disease: Influence of Exercise Therapy on Physical and Vascular Function.
The general objective is to investigate the effect of a 12 week walking exercise program on vascular endothelial function, arterial stiffness/compliance, and vascular health biomarkers in men and women with pre-dialysis type 2…
- Trial name
- DKD-EXT (NCT02112071)
- Testing
- Exercise
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- University of Minnesota
Diabetes Mellitus, Type 2, Kidney Function Tests
The Study Will Evaluate Average 24-hr Sodium Excretion During Dapagliflozin Treatment in Patients With Type 2 Diabetes Mellitus With Preserved or Impaired Renal Function or Non-diabetics With Impaired Renal Function.
The purpose of this study is to evaluate how dapagliflozin mechanism of action is impacted by Type 2 Diabetes Mellitus status and kidney function
- Trial name
- DAPASALT (NCT03152084)
- Testing
- Dapagliflozin
- Where
- 4 sites in Netherlands, Sweden
- Volunteers
- 24 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Renal Impairment in Type 2 Diabetic Subjects
The purpose of the study is to assess the effect of dapagliflozin on renal glucose clearance in type 2 diabetic subjects with mild, moderate, and severe renal impairment compared to type 2 diabetic and healthy subjects with…
- Trial name
- NCT00554450
- Testing
- Dapagliflozin
- Where
- 4 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Diabetic Nephropathy
Renoprotection in Early Diabetic Nephropathy in Pima Indians
This investigation is a randomized, double-blinded, placebo-controlled clinical trial in adult diabetic Pima Indians with normal urinary albumin excretion (albumin-to-creatinine ration less than 30 mg/g) or microalbuminuria…
- Trial name
- NCT00340678
- Testing
- Losartan
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetic Kidney Disease, Hyperuricemia
Uric Acid Lowering Trial in Youth Onset T2D
Adolescents and young adults with youth-onset type 2 diabetes (T2D) are disproportionally impacted by hyperuricemia compared to non-diabetic peers and youth with type 1 diabetes (T1D).
- Conditions
- Diabetic Kidney Disease, Hyperuricemia, Diabetes, Diabetes Mellitus, Type 2
- Trial name
- ULTRA-T2D (NCT03899883)
- Testing
- Pegloticase 8 MG/ML [Krystexxa]
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Colorado, Denver
Type 2 Diabetes Mellitus With Diabetic Nephropathy
Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria
NADPH oxidase enzymes (NOX) have been implicated in the development of several diabetic complications including diabetic nephropathy. GKT137831 is the first in class NOX1/4 inhibitor.
- Trial name
- NCT02010242
- Testing
- GKT137831
- Where
- 48 sites in United States, Australia and 4 more
- Volunteers
- 136 people
- Sponsor
- Calliditas Therapeutics AB
Microcirculation Detection in Diabetic Patients
The Predictive Value of Sidestream Dark Field Imaging in Diabetic Nephropathy
Diabetic microangiopathy refers to the pathological changes of arterioles, capillaries and venules in diabetic patients. Due to the impacts including glycol-metabolism disorder, disturbance of lipid metabolism, cytokine…
- Trial name
- NCT04403945
- Testing
- Sidestream dark field(SDF) imagining
- Where
- China
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- Third Military Medical University
Diabetes Mellitus, Type 2
Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors
Empagliflozin (Jardiance), a highly potent and selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2), was approved in Europe in May 2014 for the treatment of type 2 diabetes mellitus (T2DM) to improve glycaemic…
- Trial name
- NCT02864914
- Testing
- Empagliflozin, DPP-4 inhibitors
- Where
- United Kingdom
- Volunteers
- 333,580 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Triglyceride-Glucose Index in Diabetic Nephropathy in Type 2diaberes Mellitus Patients
The aim of the present study is to investigate the associations between the TyG index and diabetic nephropathy in patients with type2 DM .
- Trial name
- NCT05602532
- Volunteers
- 100 people
- Sponsor
- Assiut University
Type 2 Diabetes, Diabetic Kidney Disease
Renal Mechanism of SGLT2 Inhibition
Canagliflozin is an oral drug which is currently approved for use in patients with type 2 diabetes by the US Food and Drug Administration (FDA).
- Trial name
- NCT05507892
- Testing
- canagliflozin, Aminohippurate Sodium Inj 20%
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- University of Colorado, Denver
Chronic Kidney Disease stage3 and 4, Type 2 Diabetes Mellitus
Pentoxifylline Effect in Patients With Diabetic Nephropathy.(PENFOSIDINE STUDY)
One of the purposes of the management of the patient with chronic kidney disease (CKD)is to slow the decline of renal function. The mechanisms by which the renal function declines involve inflammatory and fibrotic responses due…
- Trial name
- PENFOSIDINE (NCT03664414)
- Testing
- pentoxifylline
- Where
- Mexico
- Volunteers
- 196 people
- Sponsor
- Maria Eugenia Galván Plata
Diabetic Kidney Disease, Diabetes Mellitus Type 2
Empaglifozin in Early Diabetic Kidney Disease
Background: Diabetes is common among American Indian people and diabetic kidney disease is a common complication. Kidney disease caused by diabetes can lead to the need for kidney replacement, by dialysis or kidney transplant…
- Trial name
- NCT03173963
- Testing
- Empagliflozin
- Where
- United States
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetic Kidney Disease, Diabetes Type 2
Biorepository of Biospecimen Samples in Matched Healthy Control Participants and Participants Diagnosed With Diabetic Kidney Disease, Chronic Kidney Disease, or Type 2 Diabetes
The Investigators will generate a repository of human biosamples across therapeutic areas that will be used to identify disease-associated biomarkers and potential targets with immune and multi-omics profiling.
- Conditions
- Diabetic Kidney Disease, Diabetes Type 2, Chronic Kidney Diseases, Healthy
- Trial name
- SAN-08961 (NCT05631119)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Sanguine Biosciences
Diabetic Nephropathy Type 2
Human Umbilical Cord Mesenchymal Stem Cell Infusion for Type 2 Diabetic Nephropathy
Diabetic nephropathy (DN) is a chronic kidney disease caused by diabetes. It is one of the most common and most serious microvascular complications of diabetes. Current treatment options for DN are limited.
- Trial name
- NCT07769671
- Testing
- Human umbilical cord mesenchymal stem cell injection
- Where
- China
- Volunteers
- 49 people
- Sponsor
- The First People's Hospital of Changzhou
Diabetic Nephropathy Type 2
Effect of Exercise Therapy on Type II Diabetic Neuropathic Patients
The goal of this Randomized control trial (clinical trial) is to learn about the effect of Exercise therapy on Type II Diabetic Neuropathic Patient in Pakistan ,40-70 year's old patient, will be refer by physicians.
- Trial name
- NCT06332378
- Testing
- Experimental group 1 :Ball training, Experimental group 2 :Frenkel Exercises, Control Group
- Where
- Pakistan
- Volunteers
- 90 people
- Sponsor
- Dr. Sobia Hasan
Diabetic Kidney Disease (DKD), Type 2 Diabetes
The Relationship Between Psychological Well-being, Social Support, and Disease Self-management in Patients With Diabetic Nephropathy
This study will look at the psychological well-being and social support of people with diabetic kidney disease and how these factors are related to how well they manage their condition.
- Trial name
- NCT07726589
- Where
- Taiwan
- Volunteers
- 161 people
- Sponsor
- National Taiwan University Hospital
Type 2 Diabetes Mellitus, Diabetic Kidney Disease
Evaluating the Effectiveness of a Smart Screening and Tiered Management Tool for Diabetic Kidney Disease in Primary Care: A Cluster Randomized Trial
This is a cluster-randomized controlled trial aiming to evaluate the effectiveness of an intelligent standardized screening and risk-stratified management tool for diabetic kidney disease (DKD) among adults with type 2 diabetes…
- Trial name
- SMART-DKD (NCT07707518)
- Testing
- Intervention Name Clinical decision support system for diabetic kidney disease (DKD-CDSS), Routine guideline-based diabetes management
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- First Affiliated Hospital of Chongqing Medical University